Browse drugs

…patient in sitravatinib+tislelizumab arm; 13 (6.8%) patients in docetaxel arm) (figure 1). One patient randomised to sitravatinib+tisleli…

…subfield thickness (CST) (390.13 µm vs 334.20 µm, p=0.033) than aflibercept patients. Baseline HbA1c (p=0.012) and number of bevacizumab in…

…ns (3.6%), 20 irinotecan (2.0%), 196 paclitaxel (16.6%), and 21 trastuzumab (3.1%).Conclusion and Relevance A simulation analysis of a dose…

…ti-angiogenic therapy, mainly aflibercept and bevacizumab, with faricimab as a second-line option. Personalised treatments and optimised …

…hemotherapy demonstrated significantly improved PFS compared to bevacizumab plus chemotherapy in the primary analysis. While OS favored the…

…OR ‘meningeal artery’) AND (Avastin OR Bevacizumab OR ‘TXA’ OR ‘Tranexamic Acid’ OR ‘medication adjunct’) AND (embolization). These criteria we…

…ithin one calendar week. Patients will receive a combination of atezolizumab (1200 mg) and bevacizumab (15 mg/kg) administered intravenously…

…the efficacy and safety of two cycles of induction therapy with bevacizumab and paclitaxel followed by atezolizumab and nab-paclitaxel comp…

…otal of 3,223 patients received 31,826 intravitreal injections. Bevacizumab was the most frequently prescribed drug (58.73%, n=18,690), fol…

…uctured pharmacist-led follow-up. The excellent tolerability of XELOX, with no need for rescue therapy, suggests this subgroup could …

…in the pivotal SUNLIGHT trial, supporting the benefit of adding bevacizumab to trifluridine/tipiracil in real-world practice. Safety profil…

… combination of trifluridine/tipiracil (FTD-TPI) in addition to bevacizumab (BEV) has demonstrated to have the potential to extend progress…